Skip to main content

Table 2 Infection syndrome, treatment and outcome of nosocomial bacteremia in patients infected with high MIC MRSA or low MIC MRSA

From: Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) bacteremia in Taiwan: Mortality analyses and the impact of vancomycin, MIC = 2 mg/L, by the broth microdilution method

Syndrome & treatment Vancomycin MIC < 2 N = 97 Number of patients (%) Vancomycin MIC = 2 N = 26 Number of patients (%) p-value a
Syndrome    
Primary bacteremia 18 (18.6) 5 (19.2) 0.938
Pneumonia 32 (33.0) 9 (34.6) 0.876
Catheter related infection 40 (41.2) 12 (46.2) 0.652
Prosthesis 6(6.2) 0 (0) 0.341
Infective endocarditis 6 (6.2) 0 (0) 0.341
Treatment    
Empirical glycopeptide use within 48 hours 71 (73.2) 19 (73.1) 1.000
Vancomycin trough level (mg/L) 14.9 ± 7.6 (n = 47) 13.5 ± 4.9 (n = 12) 0.176
Vancomycin trough level > 10 mg/L in first week 34 (72.3) 9 (75.0) 1.000
With a DNR orderb 26 (26.8) 11 (42.3) 0.151
Outcome    
2 week death 14 (14.4) 8 (30.8) 0.081
30 days death 27 (27.8) 13 (50.0) 0.057
  1. a: p-value calculated using a χ2 test or Fisher's exact test
  2. b: Do not resuscitate